{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:04:39Z","timestamp":1784873079620,"version":"3.55.0"},"reference-count":32,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_sjpain-2018-0083_s_001\">\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>The clinical management of neuropathic pain remains a challenge. We examined the interaction between gabapentin and NMDA receptor antagonists dextromethrophan and MK-801 in alleviating neuropathic pain-like behaviors in rats after spinal cord or sciatic nerve injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_sjpain-2018-0083_s_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Female and male rats were produced with Ischemic spinal cord injury and sciatic nerve injury. Gabapentin, dextromethorphan, MK-801 or drug combinations were injected with increasing doses. Mechanical response thresholds were tested with von Frey hairs to graded mechanical touch\/pressure, and ethyl chloride spray was applied to assess the cold sensitivity before and after injuries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_sjpain-2018-0083_s_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In spinally injured rats, gabapentin and dextromethorphan did not affect allodynia-like behaviors at doses of 30 and 20 mg\/kg, respectively. In contrast, combination of 15 or 30 mg\/kg gabapentin with dextromethorphan at 10 mg\/kg produced total alleviation of allodynia to mechanical or cold stimulation. Further reducing the dose of gapapentin to 7.5 mg\/kg and dextromethorphan to 5 mg\/kg still produced significant effect. MK-801, another NMDA receptor antagonist, also enhanced the effect of gabapentin in spinally injured rats. Similar synergistic anti-allodynic effect between dextromethorphan and gabapentin was also observed in a rat model of partial sciatic nerve injury. No increased side effect was seen following the combination between gabapentin and dextromethorphan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_sjpain-2018-0083_s_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In conclusion, the present study suggested that combining NMDA receptor antagonists with gabapentin could provide synergistic effect to alleviate neuropathic pain and reduced side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_sjpain-2018-0083_s_005\">\n                    <jats:title>Implications<\/jats:title>\n                    <jats:p>Combining NMDA receptor antagonists with gabapentin may provide a new approach in alleviating neuropathic pain with increased efficacy and reduced side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/sjpain-2018-0083","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T16:56:18Z","timestamp":1531414578000},"page":"687-693","source":"Crossref","is-referenced-by-count":19,"title":["Gabapentin and NMDA receptor antagonists interacts synergistically to alleviate allodynia in two rat models of neuropathic pain"],"prefix":"10.1515","volume":"18","author":[{"given":"Tiansheng","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Physiology and Pharmacology, Section of Integrative Pain Research, Karolinska Institutet , S-171 77 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Xia","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Section of Integrative Pain Research, Karolinska Institutet , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Wiesenfeld-Hallin","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Section of Integrative Pain Research, Karolinska Institutet , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Section of Integrative Pain Research, Karolinska Institutet , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2018,7,5]]},"reference":[{"key":"2025120910051624596_j_sjpain-2018-0083_ref_001","doi-asserted-by":"crossref","unstructured":"Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83:389\u2013400.","DOI":"10.1016\/S0304-3959(99)00154-2"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_002","doi-asserted-by":"crossref","unstructured":"Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain 2002;6(Suppl A):61\u20138.","DOI":"10.1053\/eujp.2001.0324"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_003","doi-asserted-by":"crossref","unstructured":"Nicholson B. Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand 2000;101:359\u201371.","DOI":"10.1034\/j.1600-0404.2000.0006a.x"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_004","doi-asserted-by":"crossref","unstructured":"Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofalo E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. J Am Med Assoc 1998;280:1831\u20136.","DOI":"10.1001\/jama.280.21.1831"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_005","doi-asserted-by":"crossref","unstructured":"Rice AS, Maton S. Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001;94:215\u201324.","DOI":"10.1016\/S0304-3959(01)00407-9"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_006","doi-asserted-by":"crossref","unstructured":"Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. J Am Med Assoc 1998;280:1837\u201342.","DOI":"10.1001\/jama.280.21.1837"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_007","doi-asserted-by":"crossref","unstructured":"Serpell MG. Neuropathic pain study g. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain 2002;99:557\u201366.","DOI":"10.1016\/S0304-3959(02)00255-5"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_008","doi-asserted-by":"crossref","unstructured":"Parsons CG. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 2001;429:71\u20138.","DOI":"10.1016\/S0014-2999(01)01307-3"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_009","unstructured":"Sang CN. Glutamate receptor antagonists in central neuropathic pain following spinal cord injury. In: Yezierski RP, Burchiel KJ, editors. Spinal cord injury pain: assessment, mechanisms, managements. 23. Seattle: IASP Press, 2002:365\u201377."},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_010","doi-asserted-by":"crossref","unstructured":"Collins S, Sigtermans MJ, Dahan A, Zuurmond WW, Perez RS. NMDA receptor antagonists for the treatment of neuropathic pain. Pain Med 2010;11:1726\u201342.","DOI":"10.1111\/j.1526-4637.2010.00981.x"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_011","doi-asserted-by":"crossref","unstructured":"Inturrisi CE. Preclinical evidence for a role of glutamatergic systems in opioid tolerance and dependence. Semin Neurosci 1997;9:110\u20139.","DOI":"10.1006\/smns.1997.0111"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_012","doi-asserted-by":"crossref","unstructured":"Wiesenfeld-Hallin Z. Combined opioid-NMDA antagonist therapies. What advantages do they offer for the control of pain syndromes? Drugs 1998;55:1\u20134.","DOI":"10.2165\/00003495-199855010-00001"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_013","doi-asserted-by":"crossref","unstructured":"Xu XJ, Hao JX, Aldskogius H, Seiger A, Wiesenfeld-Hallin Z. Chronic pain-related syndrome in rats after ischemic spinal cord lesion: a possible animal model for pain in patients with spinal cord injury. Pain 1992;48:279\u201390.","DOI":"10.1016\/0304-3959(92)90070-R"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_014","doi-asserted-by":"crossref","unstructured":"Gao T, Hao JX, Wiesenfeld-Hallin Z, Xu XJ. Quantitative test of responses to thermal stimulation in spinally injured rats using a Peltier thermode: a new approach to study cold allodynia. J Neurosci Methods 2013;212:317\u201321.","DOI":"10.1016\/j.jneumeth.2012.11.008"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_015","doi-asserted-by":"crossref","unstructured":"Gao T, Hao J, Wiesenfeld-Hallin Z, Wang DQ, Xu XJ. Analgesic effect of sinomenine in rodents after inflammation and nerve injury. Eur J Pharmacol 2013;721:5\u201311.","DOI":"10.1016\/j.ejphar.2013.09.062"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_016","doi-asserted-by":"crossref","unstructured":"Xu XJ, Alster P, Wu WP, Hao JX, Wiesenfeld-Hallin Z. Increased level of cholecystokinin in cerebrospinal fluid is associated with chronic pain-like behavior in spinally injured rats. Peptides 2001;22:1305\u20138.","DOI":"10.1016\/S0196-9781(01)00456-9"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_017","doi-asserted-by":"crossref","unstructured":"Hao JX, Xu XJ. Treatment of a chronic allodynia-like response in spinally injured rats: effects of systemically administered excitatory amino acid receptor antagonists. Pain 1996;66:279\u201385.","DOI":"10.1016\/0304-3959(96)03019-9"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_018","doi-asserted-by":"crossref","unstructured":"Rose MA, Kam PC. Gabapentin: pharmacology and its use in pain management. Anaesthesia 2002;57:451\u201362.","DOI":"10.1046\/j.0003-2409.2001.02399.x"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_019","doi-asserted-by":"crossref","unstructured":"Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996;271:5768\u201376.","DOI":"10.1074\/jbc.271.10.5768"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_020","doi-asserted-by":"crossref","unstructured":"Rock DM, Kelly KM, Macdonald RL. Gabapentin actions on ligand- and voltage-gated responses in cultured rodent neurons. Epilepsy Res 1993;16:89\u201398.","DOI":"10.1016\/0920-1211(93)90023-Z"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_021","doi-asserted-by":"crossref","unstructured":"Stefani A, Spadoni F, Bernardi G. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology 1998;37:83\u201391.","DOI":"10.1016\/S0028-3908(97)00189-5"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_022","doi-asserted-by":"crossref","unstructured":"Fink K, Meder W, Dooley DJ, Gothert M. Inhibition of neuronal Ca(2+) influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br J Pharmacol 2000;130:900\u20136.","DOI":"10.1038\/sj.bjp.0703380"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_023","doi-asserted-by":"crossref","unstructured":"Martin DJ, McClelland D, Herd MB, Sutton KG, Hall MD, Lee K, Pinnock RD, Scott RH. Gabapentin-mediated inhibition of voltage-activated Ca2+ channel currents in cultured sensory neurones is dependent on culture conditions and channel subunit expression. Neuropharmacology 2002;42:353\u201366.","DOI":"10.1016\/S0028-3908(01)00181-2"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_024","doi-asserted-by":"crossref","unstructured":"Singh L, Field MJ, Ferris P, Hunter JC, Oles RJ, Williams RG, Woodruff GN. The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psychopharmacology (Berl) 1996;127:1\u20139.","DOI":"10.1007\/BF02805968"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_025","doi-asserted-by":"crossref","unstructured":"Jun JH, Yaksh TL. The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat. Anesth Analg 1998;86:348\u201354.","DOI":"10.1213\/00000539-199802000-00025"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_026","doi-asserted-by":"crossref","unstructured":"Shimoyama M, Shimoyama N, Hori Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain 2000;85:405\u201314.","DOI":"10.1016\/S0304-3959(99)00283-3"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_027","doi-asserted-by":"crossref","unstructured":"Gu Y, Huang LY. Gabapentin actions on N-methyl-D-aspartate receptor channels are protein kinase C-dependent. Pain 2001;93:85\u201392.","DOI":"10.1016\/S0304-3959(01)00297-4"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_028","doi-asserted-by":"crossref","unstructured":"Dooley DJ, Mieske CA, Borosky SA. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000;280:107\u201310.","DOI":"10.1016\/S0304-3940(00)00769-2"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_029","doi-asserted-by":"crossref","unstructured":"Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudial trigeminal nucleus slices. Pain 2001;93:191\u20136.","DOI":"10.1016\/S0304-3959(01)00316-5"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_030","doi-asserted-by":"crossref","unstructured":"Lipton SA. Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci 1993;16:527\u201332.","DOI":"10.1016\/0166-2236(93)90198-U"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_031","doi-asserted-by":"crossref","unstructured":"Hao JX, Xu XJ, Urban L, Wiesenfeld-Hallin Z. Repeated administration of systemic gabapentin alleviates allodynia-like behaviors in spinally injured rats. Neurosci Lett 2000;280: 211\u20134.","DOI":"10.1016\/S0304-3940(00)00787-4"},{"key":"2025120910051624596_j_sjpain-2018-0083_ref_032","unstructured":"Yezierski RP, Burchiel KJ. Spinal injury pain: assessment, mechanism, management. Progress in pain research and management. Seattle: IASP Press, 2002:9\u201323."}],"container-title":["Scandinavian Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/sjpain.2018.18.issue-4\/sjpain-2018-0083\/sjpain-2018-0083.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/sjpain-2018-0083\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/sjpain-2018-0083\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:55:16Z","timestamp":1765284916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/sjpain-2018-0083\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,5]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,7,27]]},"published-print":{"date-parts":[[2018,10,25]]}},"alternative-id":["10.1515\/sjpain-2018-0083"],"URL":"https:\/\/doi.org\/10.1515\/sjpain-2018-0083","relation":{},"ISSN":["1877-8879","1877-8860"],"issn-type":[{"value":"1877-8879","type":"electronic"},{"value":"1877-8860","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7,5]]}}}